Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6
- 1 October 2001
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (19) , 9177-86
- https://doi.org/10.1128/jvi.75.19.9177-9186.2001
Abstract
Human immunodeficiency virus-type I (HIV-1) infection elicits antibodies (Abs) directed against several regions of the gp120 and gp41 envelope glycoproteins. Many of these Abs are able to neutralize T-cell-line-adapted strains (TCLA) of HIV-1, but only a few effectively neutralize primary HIV-1 isolates. The nature of HIV-1 neutralization has been carefully studied using human monoclonal Abs (MAbs), and the ability of such MAbs to act in synergy to neutralize HIV-1 has also been extensively studied. However, most synergy studies have been conducted using TCLA strains. To determine the nature of Ab interaction in HIV-1 primary isolate neutralization, a panel of 12 anti-HIV-1 human immunoglobulin G (IgG) MAbs, specific for epitopes in gp120 and gp41, were used. Initial tests showed that six of these MAbs, as well as sCD4, used individually, were able to neutralize the dualtropic primary isolate HIV-1(89.6); MAbs giving significant neutralization at 2 to 10 microg/ml included 2F5 (anti-gp41), 50-69 (anti-gp41), IgG1b12 (anti-gp120(CD4bd)), 447-52D (anti-gp120(V3)), 2G12 (anti-gp120), and 670-D (anti-gp120(C5)). For studies of reagent interaction, 16 binary combinations of reagents were tested for their ability to neutralize HIV-1(89.6). Reagent combinations tested included one neutralizing MAb with sCD4, six pairs consisting of two neutralizing MAbs, and nine pairs consisting of one neutralizing MAb with another non-neutralizing MAb. To assess the interaction of the latter type of combination, a new mathematical treatment of reagent interaction was developed since previously used methods could be used only when both reagents neutralize. Synergy was noted between sCD4 and a neutralizing anti-gp120(V3) MAb. Antagonism was noted between two pairs of anti-gp41 MAbs (one neutralizing and one non-neutralizing). All of the other 13 pairs of MAbs tested displayed only additive effects. These studies suggest that Abs rarely act in synergy to neutralize primary isolate HIV-1(89.6); many anti-HIV-1 Abs act additively to mediate this biological function.Keywords
This publication has 153 references indexed in Scilit:
- Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibodyVirus Research, 1996
- Combination effect on HIV infection in vitro of soluble CD4 and HIV-neutralizing antibodiesArchiv für die gesamte Virusforschung, 1994
- Antigenic Variation in gp120s from Molecular Clones of HIV-1 LAIAIDS Research and Human Retroviruses, 1993
- Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120AIDS Research and Human Retroviruses, 1992
- Synergy Between Human Monoclonal Antibodies to HIV Extends Their Effective Biologic Activity Against Homologous and Divergent StrainsAIDS Research and Human Retroviruses, 1992
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987
- Synergistic Neutralization of Rubella Virus by Monoclonal Antibodies to Viral HaemagglutininJournal of General Virology, 1987
- The synergistic neutralization of Newcastle disease virus by two monoclonal antibodies to its haemagglutinin-neuraminidase proteinArchiv für die gesamte Virusforschung, 1986
- Lethal 17D Yellow Fever Encephalitis in Mice. I. Passive Protection by Monoclonal Antibodies to the Envelope Proteins of 17D Yellow Fever and Dengue 2 VirusesJournal of General Virology, 1986
- Conformational Changes in Sindbis Virus E1 Glycoprotein Induced by Monoclonal Antibody BindingJournal of General Virology, 1983